A Phase II Trial of Nivolumab With Chemotherapy Followed by Maintenance Nivolumab in Patients With Pleural Mesothelioma After Surgery: The NICITA Study Protocol-Reference-Cited by-同舟云学术

A Phase II Trial of Nivolumab With Chemotherapy Followed by Maintenance Nivolumab in Patients With Pleural Mesothelioma After Surgery: The NICITA Study Protocol

Published:2021-03 Issue:2 Volume:22 Page:142-146
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Shah Rajiv,Klotz Laura V.,Chung Inn,Feißt Manuel,Schneider Marc A.^ORCID,Riedel Johanna,Bischoff Helge,Eichhorn Martin E.,Thomas Michael

Funder

Bristol-Myers Squibb

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference29 articles.

1. Life expectancy in pleural and peritoneal mesothelioma;Shavelle;Lung Cancer Int,2017

2. Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)-Medicare investigation of treatment patterns and overall survival;Beebe-Dimmer;Clin Epidemiol,2016

3. Frequency of use and predictors of cancer-directed surgery in the management of malignant pleural mesothelioma in a community-based (Surveillance, Epidemiology, and End Results [SEER]) population;Flores;J Thorac Oncol,2010

4. A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma;Cao;Lung Cancer,2014

5. Emerging therapies in malignant pleural mesothelioma;Cinausero;Crit Rev Oncol Hematol,2019

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multimodal Treatment of Pleural Mesothelioma with Cytoreductive Surgery and Hyperthermic Intrathoracic Chemotherapy: Impact of Additive Chemotherapy;Cancers;2024-04-20

2. Combination therapy with nivolumab (anti-PD-1 monoclonal antibody): A new era in tumor immunotherapy;International Immunopharmacology;2022-12

3. Multimodal therapy of epithelioid pleural mesothelioma: improved survival by changing the surgical treatment approach;Translational Lung Cancer Research;2022-11

4. Epidemiologie, Diagnostik und Therapie des Pleuramesothelioms;InFo Hämatologie + Onkologie;2022-07-28

5. Recent Advances of Immune Checkpoint Inhibition and Potential for (Combined) TIGIT Blockade as a New Strategy for Malignant Pleural Mesothelioma;Biomedicines;2022-03-14